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ened in the group receiving ceﬁxime (mean 15.0 hours vs
29.3 hours, p = 0.028). However, there was no signiﬁcant dif-
ference with respect to the rate of clearance of Salmonella
from stool (p = 0.843). All followed-up samples after com-
pleting therapy, remained sensitive in vitro to ceﬁxime.
There was no relapse of the same pathogen found.
Conclusion: The clinical trial showed that ceﬁxime could
shorten the time to defervescence and the duration of
diarrhea signiﬁcantly. Prolonging the period of carriage or
increasing the risk of relapse was not found in this study.
Ceﬁxime could be considered in acute, uncomplicated,
Salmonella enteritis in children with mucoid/bloody diar-
rhea.
doi:10.1016/j.ijid.2010.02.1923
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Evaluation of the pharmacodynamics of Daptomycin
(DAP)-Rifampin (RIF) combinations with Staphylococcus
aureus using various in vitro methods
S. Zinner1,∗, M. Smirnova2, E. Strukova2, A. Firsov2
1 Mount Auburn Hospital, Harvard Medical School, MA, MA,
USA
2 Gause Institute for Antibiotics, Moscow, Russian Federa-
tion
Background: The evaluation of antibiotic combinations
is often based on traditional checkerboard techniques (CT)
that might or might not provide optimal interpretations. In
this study, DAP plus RIF combinations were tested with S.
aureus using CT as well as time-kill curves at constant and
changing antibiotic concentrations – static studies (SS) and
dynamic studies (DS), respectively.
Methods: A clinical isolate S. aureus 866 (MIC of DAP
0.5mg/L, MIC of RIF 0.016mg/L) was tested using CT at DAP
concentrations ranging from 0 to 2mg/L and RIF concentra-
tions ranging from 0 to 0.06mg/L. In SS, the same organism
was exposed to DAP (0.5, 1, 2, 4, 8 and 6mg/L), alone and in
combination with RIF (DAP/RIF 1:1.5) over a 24-hour period.
In DS, S. aureus was exposed to daily administered DAP and
DAP+RIF for 5 consecutive days; the simulated ratios of area
under concentration-time curve (AUC) to the MIC were 50
and 50+75, respectively. The antimicrobial effects observed
in SS and DS were expressed by areas between the bacte-
rial concentration — time curves with and without antibiotic
(ABBCs).
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Results: Based on the CT data, DAP+RIF combinations
ere additive or indifferent (FIC index = 1). Based on ABBC
nalysis of the SS data, DAP+RIF was synergistic at relatively
ow AUC/MICs of DAP (24-96) or additive at higher AUC/MICs
f DAP (192-770). For example, the 24-hour ABBC of DAP
AUC/MIC 48) + RIF (AUC/MIC 72) was 9-fold greater than
hat of DAP (AUC/MIC 48). Similar differences in the effects
f DAP+RIF and DAP were established in DS: the 120-hour
BBC was 13 times greater in simulations of the combination
han DAP alone.
Conclusion: These data suggest that (1) checker-
oard technique-based evaluations of daptomycin+rifampin
ombinations can be misleading, and (2) in vitro pharmaco-
ynamic data obtained in static systems are predictive of
hose in dynamic studies.
oi:10.1016/j.ijid.2010.02.1924
9.008
he effectiveness of oral suppression in high risk pros-
hetic joint infections after total knee arthroplasty
. McBroom1,∗, D.J. Barbaro2
University of North Texas Health Science Center, Fort
orth, TX, USA
Tarrant County Infectious Disease Associates, Fort Worth,
X, USA
Background: Prosthetic joint infection (PJI) is a rare but
erious complication of total knee arthroplasty (TKA) and is
frequent reason for failure to retain the prosthesis. Recent
tudies have reported success rates of >80 percent with
ebridement and retention of prosthesis between 2 to 5-year
ollow-up periods. Lack of consensus on deﬁnitions of PJI
nd risk factors between centers makes evaluation of true
isk factors and outcomes a challenge. Though improved suc-
ess rates have been reported for the conservative approach
f debridement, intravenous (IV) antimicrobial therapy, and
rosthesis retention, little data exists on combining the use
f oral suppressive therapy with this treatment option.
Methods: Nine year retrospective study of 28 high risk PJI
atients after TKA who had been treated with debridement,
ix weeks IV antimicrobial therapy and prosthesis retention,
r the same treatment with oral suppressive therapy and had
two to ﬁve year follow-up to ascertain the effectiveness
f oral suppressive therapy, excluding potential confound-
ng factors such as chemotherapy, HIV treatment, or steriod
herapy. Statististical analysis involved estimation of cumu-
ative probability of treatment failure using Kaplan Meier
ethod and total curve comparison was obtained by using
he Mantel-Cox logrank method. Fisher’s exact test and the
ilcoxon rank sum test were used for univariate analysis.
Results: The 2-year cumulative probability of failure for
ral suppressive therapy was 7% (95% CI: 0.04 to 27.5)
ompared to 42% (95% CI: 17.7 to 66.07) for the control
roup. Oral suppressive therapy was signiﬁcantly differ-
nt than control (P = 0.033).Conclusion: Treating high risk
atients with only six weeks IV antimicrobial therapy and
ebridement, especially in early postoperative infections,
ould lead to treatment failure sooner than when treating
atients with oral suppressive therapy. The effectiveness
f this treatment could reﬂect the importance of using
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ifampin/vancomycin or similar combinations during the six
eeks preceding the baseline of this study.
oi:10.1016/j.ijid.2010.02.1925
9.009
opulation pharmacokinetics of meropenem in pediatric
atients: a concurrent analysis of the plasma and urine
oncentration data
. Ikawa ∗, N. Morikawa, K. Ikeda, M. Miki, M. Kobayashi
Hiroshima University, Hiroshima, Japan
Background: This study aimed to develop a population
harmacokinetic model for meropenem in Japanese pedi-
tric patients, speciﬁcally focusing on the drug urinary
xcretion process. This study also aimed to use this model
o assess the pharmacodynamics of meropenem regimens
gainst common bacterial populations.
Methods: Pharmacokinetic data (229 plasma samples and
1 urine samples) were collected from 40 infected children
age, 0.2—14.8 years; body weight, 3.8—64.0 kg) in nine
eparate studies. The data were concurrently ﬁtted into
multi-compartment model using the NONMEM program.
he developed model was then used for a pharmacody-
amic Monte Carlo simulation to estimate the probabilities
f attaining the bactericidal target (40% of the time for
hich the free drug concentration remains above the MIC
or the bacterium).
Results: In the ﬁnal population pharmacokinetic model,
ody weight (BW, kg) was the most signiﬁcant covariate
s follows: CLr (L/h) = 0.254 3 BW, CLnr (L/h) = 3.45, Vc
L) = 0.272 3 BW, Q (L/h) = 1.65 and Vp (L) = 0.228 3 BW,
here CLr and CLnr are the renal and non-renal clearances,
p and Vc are the volumes of distribution of the central and
eripheral compartments, and Q is the intercompartmen-
al (central—peripheral) clearance. The pharmacodynamic
ssessment based on this model showed that regimens of
0—40mg/kg, three times a day (0.5-h infusions), achieved
target attainment probability of >80% against clinical
solates of Escherichia coli (MIC90 = 0.03mg/L), Streptococ-
us pneumoniae (MIC90 = 0.5mg/L), methicillin-susceptible
taphylococcus aureus (MIC90 = 0.12mg/L), Haemophilus
nﬂuenzae (MIC90 = 0.25mg/L) and Pseudomonas aeruginosa
MIC90 = 1mg/L), in most typical patients (BW = 10, 20 and
0 kg).
Conclusion: These results provide a better understand-
ng of the pharmacokinetics of meropenem in Japanese
ediatric patients. They are also useful in the choice of a
eropenem regimen based on the BW of the patient and
he susceptibility of the causative bacteria.
oi:10.1016/j.ijid.2010.02.1926
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ppropriate use of ﬂuoroquinolones in a Lebanese ter-
iary medical center
. Kabbara ∗, P. Rahbany, S. Al-Natour
Lebanese American University, Byblos, Lebanon
Background: Fluoroquinolones are among themost widely
rescribed antibiotics especially for respiratory and urinary
ract infections. However, concerns about increasing resis-
ant micro-organisms associated with the use of these agents
ave emerged in both community and hospital settings. This
as been particularly a rising major problem in Lebanon
s the resistance to ﬂuoroquinolones has reached 30-40%
y 2008 (for E.coli and Klebsiella species). The primary
bjective of this study is to assess the appropriate use of
uoroquionolones in a Lebanese tertiary medical center by
valuating the appropriate indication, dose, dosage adjust-
ent in renal impairment, and the duration of treatment.
Methods: We conducted a prospective observational
tudy at Raﬁc Harriri University Hospital in Beirut, Lebanon
etween January and June 2009. We identiﬁed 118 patients
eceiving broad spectrum ﬂuoroquinolones (levoﬂoxacin,
iproﬂoxacin and moxiﬂoxacin). The majority of patients
ere in internal medicine ﬂoors or in the intensive care unit.
data collection form inculding all pertinent information
as used. Patients were followed from initiation of ﬂuoro-
uinolone therapy to the discharge date. The assessment
or the appropriate use was based on relevant guidelines
rom the Infectious Disease Society of America, manufac-
urer package inserts and clinical judgment. Monitoring of
lood glucose levels with ﬂuoroquinolone therapy was also
valuated.
Results: The patient population was predominantly male
62.7%) and the mean age was 62.8 years. About one third
f the patients (29.6%) had decreased renal function neces-
itating dosage adjustment of ciproﬂoxacin or levoﬂoxacin.
he main indications were community acquired pneumonia
nd diabetic foot infections. Cultures were taken in only
9.3% of patients. Of the positive cultures, the most com-
on isolated micro-organisms were E. coli and Pseudomonas
eruginosa. The ﬁnal percentage of ﬂuoroquinolone appro-
riate indication, dose and duration of therapy was 93.2%,
4.5% and 57.6% respectively (which were also calculated
or each drug separately). 57.1% of patients did not receive
he appropriate dose adjustment according to the level of
enal dysfunction (calculated by using Cockcroft-Gault equa-
ion). Baseline blood glucose was monitored in only 21.5% of
atients.
Conclusion: The major clinical interventions that need
mprovement in our tertiary medical center are adequate
enal adjustment of the dose of ﬂuoroquinolones and the
uration of therapy.
oi:10.1016/j.ijid.2010.02.1927
